Literature DB >> 1472742

Medical risk factors in diabetic patients with foot ulcers and severe peripheral vascular disease and their influence on outcome.

J Apelqvist1, J Larsson, C D Agardh.   

Abstract

The association between medical risk factors and the outcome of foot ulcers was evaluated in 208 consecutive diabetic patients with severe peripheral vascular disease (systolic toe blood pressure < or = 45 mm Hg). All patients were treated and followed by the same foot care team. Eighty patients healed primarily, 83 healed after a minor or major amputation, and 45 died. The systolic toe blood pressure was higher among primary healed (30 +/- 13 mm Hg) compared with amputated (22 +/- 15 mm Hg; p < 0.001) and deceased patients (20 +/- 14 mm Hg; p < 0.001). The patients were comparable regarding age, sex, and diabetes and wound duration. Only 41 (19%) patients had intermitten claudication, whereas 153 (77%) lacked palapble pedal pulses, 36% of whom healed primarily. Rest pain occurred in 72 (33%) patients, 38 (47%) of whom had an amputation and 18 (25%) who healed primarily (p < 0.01). Peripheral edema and proteinuria were more common among patients who healed after amputation compared with those who healed primarily (p < 0.001 and p < 0.01, respectively). Signs of sensory neuropathy were found in 158 (77%) patients. There were no differences concerning cardiovascular disease, smoking habits, or short-term metabolic control between patients who healed primarily or after an amputation. In conclusion, diabetic patients with foot ulcers and severe peripheral vascular disease with low systolic toe blood pressure were not excluded from the possibility of primary healing. The most important risk factors for amputation were a systolic toe pressure of less than 30 mm Hg, peripheral edema, rest pain, and proteinuria.

Entities:  

Mesh:

Year:  1992        PMID: 1472742     DOI: 10.1016/1056-8727(92)90032-g

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  8 in total

Review 1.  Cost-effective management of diabetic foot ulcers. A review.

Authors:  G Ragnarson-Tennvall; J Apelqvist
Journal:  Pharmacoeconomics       Date:  1997-07       Impact factor: 4.981

2.  Prognostic value of the clinical examination of the diabetic foot ulcer.

Authors:  D Edelman; D M Hough; K N Glazebrook; E Z Oddone
Journal:  J Gen Intern Med       Date:  1997-09       Impact factor: 5.128

3.  Costs of deep foot infections in patients with diabetes mellitus.

Authors:  G R Tennvall; J Apelqvist; M Eneroth
Journal:  Pharmacoeconomics       Date:  2000-09       Impact factor: 4.981

Review 4.  Optimal treatment of infected diabetic foot ulcers.

Authors:  Edward B Jude; Philip F Unsworth
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

5.  Distribution of systemically administered ampicillin, benzylpenicillin, and flucloxacillin in excisional wounds in diabetic and normal rats and effects of local topical vasodilator treatment.

Authors:  S E Cross; M J Thompson; M S Roberts
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

6.  Ventral Windowed Total Contact Casts Safely Offload Diabetic Feet and Allow Access to the Foot.

Authors:  Dirk Hochlenert; Claudia Fischer
Journal:  J Diabetes Sci Technol       Date:  2020-10-23

7.  Cross-sectional correlations between the toe brachial index and lower limb complications in older people.

Authors:  Jennifer A Sonter; Vivienne H Chuter
Journal:  Int Wound J       Date:  2015-12-09       Impact factor: 3.315

8.  Lower resource utilization for patients with healed diabetic foot ulcers during participation in a prevention program with foot temperature monitoring.

Authors:  Adam L Isaac; Timothy D Swartz; Mark L Miller; Daniel J Short; Eleanor A Wilson; Jamie L Chaffo; Eric S Watson; Haihong Hu; Brian J Petersen; Jonathan D Bloom; Nicole J Neff; David R Linders; Simon J Salgado; Jessica L Locke; Michael A Horberg
Journal:  BMJ Open Diabetes Res Care       Date:  2020-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.